EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anders Jeppsson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyllner, M.
Right arrow Articles by Jeppsson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyllner, M.
Right arrow Articles by Jeppsson, A.
Related Collections
Right arrow Cardiac - other

Eur J Cardiothorac Surg 2005;28:254-258
© 2005 Elsevier Science NL


Original articles

Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery

Monica Hyllner a , * , Erik Houltz a , Anders Jeppsson b

a Department of Cardiothoracic Anaesthesiology & Intensive Care, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden
b Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden

Received 16 December 2004; received in revised form 12 April 2005; accepted 15 April 2005.

* Corresponding author. Tel.: +46 31 342 1000; fax: +46 31 413 862. (Email: monica.hyllner{at}vgregion.se).

Abstract

Objective: Massive perioperative bleeding is a potential complication of cardiac surgery, and may persist despite conventional interventions. RFVIIa is being increasingly used as additional therapy, and the aim of the present study was to describe our experience with rFVIIa in the management of life-threatening bleeding in adult cardiac surgery. Methods: Retrospective chart review of 24 patients undergoing a variety of cardiac procedures was performed at Sahlgrenska University Hospital between January and August 2004. The patients developed life-threatening bleeding during or after surgery despite conventional medical therapy and transfusion of blood products, and received rFVIIa as additional therapy. Results: RFVIIa was administered as a median bolus dose of 60µg/kg. Nineteen patients received one dose of rFVIIa; the bleeding stopped or decreased in 18 of them. Five patients received repeated doses of rFVIIa. Fifteen patients were reexplored due to massive postoperative bleeding or cardiac tamponade and a surgical source of bleeding was identified in six of these patients. A statistically significant reduction in chest drain losses after administration of rFVIIa was demonstrated. No adverse reactions were noted. Conclusions: RFVIIa was successfully used as an additional therapy both during and after cardiac surgery, when bleeding was refractory to conventional methods. Bleeding stopped eventually in all patients and none of the patients exsanguinated.

Key Words: Cardiac surgery • Recombinant activated factor VII • Life-threatening bleeding




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
M. Ranucci, G. Isgro, G. Soro, D. Conti, and B. De Toffol
Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials
Arch Surg, March 1, 2008; 143(3): 296 - 304.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou
Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review
Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Filsoufi, J. G. Castillo, P. B. Rahmanian, C. Scurlock, G. Fischer, and D. H. Adams
Effective Management of Refractory Postcardiotomy Bleeding With the Use of Recombinant Activated Factor VII
Ann. Thorac. Surg., November 1, 2006; 82(5): 1779 - 1783.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.